A Randomized, Double-Blind, Placebo-Controlled Crossover Study Of The Anti-Inflammatory Compound Anatabine To Treat Pain in GWI Patients

Abstract

The goal of the proposed clinical trial was to target one of the major complaints from veterans with Gulf War Illness (GWI) - namely chronic pain and inflammation - using a compound with a history of safe use in humans and efficacy in an animal model of GW agent exposure. Musculoskeletal pain and associated inflammation are some of the most debilitating symptoms of GWI, and the national War Related Illness and Injury Study Centers (WRIISC) report pain as the major complaint from GW veterans (90%), exceeding the next most prevalent symptom, fatigue, by three fold. Identifying effective, safe, and tolerable treatments will alleviate major aspects of the currently untreatable multisymptom condition.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2018
Accession Number
AD1055799

Entities

People

  • Fiona Crawford

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biomedical Research
  • Clinical Trials
  • Commerce
  • Department Of Defense
  • Dietary Supplements
  • Diseases And Disorders
  • Governments
  • Institutional Review Board
  • Local Governments
  • Medical Personnel
  • Muscular Diseases
  • Pain
  • Patent Applications
  • Persian Gulf Syndrome
  • Professional Development
  • Standards
  • Training

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.